Background. Whereas human immunodeficiency virus (HIV) subtype B-infected individuals generally progress to AIDS within 8-10 years, limited data exist for other clades, especially from Africa. We investigated rates of HIV disease progression of clade C-infected South African women.
Human immunodeficiency virus (HIV) disease progression is highly variable between individuals and populations and is determined by genetic, immunologic, virologic, and environmental factors [1] [2] [3] . CD4 + T-cell decline has been recognized as one of the major markers of the rate of HIV disease progression. Once CD4 counts drop below 200 cells/µL, the risk of opportunistic infections and death increases dramatically. In addition to CD4 decline, disease progression can be defined by time to antiretroviral therapy (ART) initiation, diagnosis of AIDS-defining illnesses, or death. Whereas the majority of HIV-infected individuals (70%-80%) fall into an intermediate category, rapid progression and long-term nonprogression represent extreme phenotypes with respect to CD4 decline [4] . In addition, the infecting subtype can have a significant impact on the rate of CD4 decline [5, 6] . This has been best defined for clades A and D in East Africa, where studies demonstrated a shorter median time to AIDS in subtype D-infected individuals than in subtype Ainfected individuals [7] [8] [9] . Studies from sub-Saharan Africa suggest faster disease progression in subtype C-infected individuals [10, 11] , despite observations that subtype C may replicate less efficiently than subtype B [12] .
A major immunologic predictor of progression is the level of host immune activation, which predicts rates of CD4 decline more accurately than plasma viral load (VL) [13] . African populations have reportedly higher levels of immune activation than US populations, possibly linked to a higher burden of comorbidities and micronutrient deficiencies [14, 15] . Indirect immune activation caused by microbial translocation and loss of gut-associated CD4 cells has also been demonstrated in HIV rapid progressors [16] . Another major host predictor of disease progression is the human leukocyte antigen (HLA) background. HLA-B35, B8, B45, and B53 have been associated with rapid progression, whereas HLA-B57 and B27 are more common in slow progressors [11, [17] [18] [19] .
Results from mostly subtype B-infected cohorts suggest that rapid progression is uncommon, with only about 5% of individuals progressing from acute HIV infection to AIDS within 3 years [20, 21] . However, there are limited data on disease progression in other subtypes, especially from prospective African cohorts infected with subtype C. This study describes HIV type 1 (HIV-1) disease progression in South African women and identifies host and viral factors associated with progression.
METHODS

Study Population
Between August 2004 and May 2005, a cohort of HIV-uninfected women at high risk of HIV acquisition was enrolled into the Centre for the AIDS Programme of Research in South Africa (CAP-RISA) 002 Acute Infection Study, recruited at 2 sites within the province of KwaZulu-Natal in South Africa-an urban site in Durban and a rural site in Vulindlela. The aim of the study was to describe immunologic, virologic, and clinical characteristics of HIV-1 subtype C acute infection and investigate the natural history of HIV-1 subtype C infection [22] . Women aged ≥18 years who self-reported as sex workers or having >3 sexual partners within the last 3 months were screened. Those testing HIV negative were offered enrollment and followed for up to 4 years, with monthly testing to identify acute HIV infections [23] . In addition, women were also recruited from a rural family planning and sexually transmitted infection (STI) clinics in Durban [24] with quarterly HIV testing and follow-up. Written informed consent was obtained from all participants, and ethical approval for the study was granted by the University of KwaZulu-Natal (E013/04), University of Cape Town (025/2004), and University of the Witwatersrand (M040202).
HIV Testing and Time of Infection
HIV diagnosis was based on antibody and/or nucleic acid detection. Two point-of-care antibody tests were used, the third-generation Determine (Abbott Laboratories, Abbott Park, Illinois) and Capillus (Trinity Biotech, Jamestown, New York). An HIV enzyme-linked immunosorbent assay was performed to confirm HIV diagnosis using the HIV enzyme immunoassay BEP 2000 (Dade Behring, Marburg, Germany). HIV reverse transcription polymerase chain reaction (RT-PCR) testing was performed at every testing with antibody-negative results. COBAS Amplicor version 1.5 RT-PCR testing (Roche Diagnostics, Rotkreuz, Switzerland) was performed using a pooling strategy of 24 samples per pool [25, 26] . Time of infection was estimated as the midpoint between last antibody-negative and first antibody-positive test or 14 days before a positive RT-PCR result for those diagnosed preseroconversion.
Once HIV diagnosis was confirmed, women were enrolled into the acute HIV infection cohort. The visit structure was divided into 3 phases: weekly to fortnightly visits up to 3 months postinfection (acute infection), monthly visits from 3 to 12 months (early infection), and quarterly visits thereafter (established infection) until ART initiation. Samples for immunologic, virologic, and clinical parameters were collected, and VL and CD4 counts (FACSCalibur Flow Cytometer, BD Biosciences, San Jose, California) were measured at each visit. Screening for STIs with multiplex PCR testing and Gram stain for bacterial vaginosis were performed at enrollment and every 6 months thereafter [27] . Women with positive results were recalled for treatment or referred to the nearest clinic. Any other STIs were treated syndromically on presentation according to South African National Guidelines.
High-resolution HLA typing was performed on all participants. DNA was extracted from either peripheral blood mononuclear cells or granulocytes using the Pel-Freez DNA Isolation kit. HLA-A, -B, and -C typing was performed by sequencing of exons 2, 3, and 4 using Atria AlleleSeqr kits (Abbott), and data were analyzed using Assign-SBT 3.5 (Conexio Genomics). Any ambiguities resulting from either polymorphisms outside the sequenced exons or identical heterozygote combinations were resolved using sequence-specific primers.
Statistical Analysis
Basic descriptive statistics were used to summarize frequencies and timing of the first occurrences of clinical signs and symptoms. Linear mixed models were used to estimate the CD4 slope within 12 months of HIV infection. Kaplan-Meier analyses were carried out using estimated time of infection to endpoints of CD4 counts of <200, <350, and <500 cells/µL. Stratified analyses using 3-and 6-month postinfection VL (<5 and ≥5 log copies/mL) were also performed. Whereas rapid disease progression is currently defined as ≥2 CD4 measurements <350 cells/µL within 3 years of seroconversion [28] , we conservatively defined it as 2 consecutive CD4 counts <350 cells/ µL between 6 months (to exclude seroconversion decline) and 24 months postinfection. Non-rapid progressors (NRPs) were those maintaining a CD4 count >350 cells/µL beyond 24 months. Baseline differences between rapid progressors (RPs) and NRPs were assessed by Wilcoxon rank-sum and Fisher exact tests. Cox proportional hazards regression modeling was used to assess predictors of rapid progression. Participants who did not progress rapidly were censored at their last follow-up visit or 24 months postinfection, whichever came first. Predictors in the unadjusted model with P values <.20, or deemed important, were included in the adjusted model. Statistical analysis was performed using SAS software, version 9.3 (SAS Institute Inc., Cary, North Carolina); graphs were prepared using Graph Pad Prism 5.
RESULTS
Baseline Characteristics of the Cohort
Of the 245 HIV-negative women followed up monthly for 4 years, 35 (14.3%) acquired HIV. The 594 HIV-negative women followed quarterly from seroincidence cohorts yielded 39 HIV seroconversions; 27 of these women consented to further follow-up. HIV incidence rates were similar between cohorts (6.5/100 person-years [95% confidence interval {CI}, 4.6-8.9] for the N = 594 women and 7.2/100 person-years [95% CI, 4.5-9.8] for the N = 245 women) [29] , and the cohorts had minimal influence on progression rates (hazard ratio Demographic, behavioral, and clinical characteristics of these women are summarized in Table 1 . The median age at HIV infection was 25 years (IQR, 21-33 years), and most women (71.0%) were either married or had a stable partner. At enrollment into the acute HIV infection cohort, STIs were common (44.3%), and most women (91.9%) were seropositive for herpes simplex virus type 2 (HSV-2). The overall mean CD4 count at this first postseroconversion timepoint was 520 cells/µL. This was significantly lower than the preinfection CD4 counts (mean CD4 count, 993 cells/µL available for 25 of 62 women; P < .001). The CD4 counts differed significantly between RPs and NRPs (413 vs 603 cells/µL; P < .001; Table 1 ) at first postseroconversion with a mean log VL of 4.62 log copies/mL (SD = 0.92) and higher levels in RPs than NRPs (4.96 vs 4.36 log copies/mL; P = .009).
Prospective Analysis 2% from preinfection to seroconversion; P = .023). There were no significant differences in Figure 1 . Superimposed Kaplan-Meier graphs of time to CD4 count <200, <350, and <500 cells/µL since estimated date of infection. Abbreviations: CI, confidence interval; IR, incidence rate; PY, person-years.
the preinfection CD4 counts between RPs and NRPs (mean CD4 count, 960 cells/µL and 1029 cells/µL, respectively; P = .649) (Supplementary Figure 1) . These data suggest that severe depletion of CD4 T cells in early infection is highly predictive of subsequent disease progression.
Plasma Viral Loads as a Predictor of Rapid Disease Progression
The mean of the first available VL in this cohort (including the available preseroconversion RT-PCR results) was 4.83 log copies/mL (SD, 1.10), at a median of 31 days postinfection (IQR, 14-58 days), likely representing the decline following peak viremia. Mean VL dropped to 4.26 (SD, 0.91) and 4.20 (SD, 0.95) log copies/mL at 6 and 12 months, respectively, representing setpoint viremia. Viral loads were significantly higher in RPs than in NRPs, with a mean VL at 3 months postinfection of 4.86 log copies/mL (SD, 0.62) compared with 4.13 log copies/ mL (SD, 0.86; P < .001).
To further determine the impact of VL on disease progression, we compared CD4 decline in participants with high VL, using a cutoff of 5 log copies/mL. Participants with higher VL at 3 months postinfection were more likely to reach a CD4 count <350 cells/µL sooner (log-rank P < .001), compared with women with lower VL. At 24 months postinfection, 77% of those who had high VL at 3 months reached the endpoint, compared with 35% of the lower VL group. The median time to endpoint for those with high VL was 6.7 months from infection compared with 34.6 months with a low VL (Figure 2 ). Similar results were obtained for VL at 6 months postinfection. The data for a CD4 count endpoint of <500 cells/µL were even more dramatic, with the probability of reaching the endpoint by 2 
Timing of Clinical Conditions From Acute Infection
The timing of the first presentation of clinical events during the acute phase and subsequent course of HIV infection is shown in Figure 3 . Almost all participants experienced lymphadenopathy (98.4%), and many presented with upper respiratory tract infection (38.7%), vaginal discharge (87.1%), and genital ulcer disease (19.4%) during acute HIV infection. Whereas women presented with fungal infection and nonspecific skin rashes throughout the disease course, other infections such as shingles, lower respiratory tract infections, and tuberculosis were diagnosed later during HIV infection. Aside from 2 participants who died of HIV-related diseases (tuberculosis and cryptococcal meningitis), there were no other AIDS-defining diagnoses in the cohort. Of 41 participants, who became eligible and were referred for ART during the study, 37 have so far initiated ART.
Predictors of Rapid HIV Disease Progression
In the unadjusted analysis, associations were noted between rapid progression and not having a regular partner (HR, 3.03 [95% CI, 1.07-8.53]; P = .036), having ≥2 sexual partners in the 3 months prior to infection (HR, 2.06 [95% CI, .96-4.41]; P = .063), and being enrolled at the urban site (HR, 2.47 [95% CI, .85-7.14]; P = .096). CD4 count decline from pre-HIV infection (HR, 1.56 [95% CI, 1.12-2.17 per 10% decrease]; P = .008) and incident hepatitis B infection during the first 6 months (HR, 8.98 [95% CI, 2.21-36.47]; P = .002) were also predictive of rapid disease progression. Notably, in the 3 cases of incident hepatitis B infection identified between HIV acquisition and 6 months postinfection, all rapidly progressed to a CD4 count <350 cells/µL. No associations were observed for age, education, sex worker status, or clinical data including a history of tuberculosis, body mass index, an abnormal full blood count result, or STIs at enrollment into the acute HIV infection cohort (Table 2) .
Overall, the best independent predictors of CD4 decline and rapid disease progression were CD4 count at 3 months (HR, 2.07 [95% CI, 1.31-3.28 per 100 cells/µL decrease]; P = .002), VL during early infection (HR, 3.82 [95% CI, 1.51-9.67 per 1-log increase]; P = .005), and hepatitis B infection at the time of HIV infection (HR, 4.54 [95% CI, 1.31-15.69]; P = .017). Conversely, the best predictors of non-rapid progression were any of the previously described protective HLA genotypes (B*1302, B*27, B*57, B*5801, B*8101), with an HR of 0.19 (95% CI, .05-.74; P = .016).
DISCUSSION
The rate of HIV disease progression is highly variable, with important implications for both clinical disease management and program planning. Previous studies have estimated that rapid HIV progression is relatively uncommon, using definitions of CD4 decline within 3 years [31] . Here, we show that nearly half of the clade C-infected women met our conservative definition of rapid disease progression (CD4 decline to <350 cells/ [32] . The high proportion of women experiencing rapid disease progression suggests that this may be the dominant phenotype in the natural history of HIV-1 disease in our setting. This finding supports the argument of starting ART early, especially in settings where the risk of coinfections such as tuberculosis is high. The 2013 WHO guidelines suggest starting ART at a CD4 count of <500 cells/µL [30] . Here, we showed that nearly three-quarters of HIV-infected individuals will reach this threshold within 1 year of infection. Preinfection CD4 counts in this population were similar to those in developed countries, with no association between preinfection CD4 counts and disease progression rate. A striking finding in this study is the magnitude of CD4 cell depletion during acute HIV infection, with nearly half of preinfection CD4 cells lost within the first 6 months of HIV infection. We observed very little CD4 cell rebound after acute infection, in contrast to the modest and transient loss described in most published studies. The rate of CD4 cell loss in the rapid progressors is higher than that observed in other HIV-1 subtype C-infected cohorts [5] .
We have previously shown in this cohort that the magnitude or breadth of T-cell recognition across the expressed genome at 3 months had no association with viral setpoint at 12 months [33] and that recognition of more conserved epitopes in Gag tended to associate with slow disease progression in the first year of infection. This was in parallel with the accumulation of less differentiated Gag-specific CD8 + T memory cells by 6-9 months postinfection in individuals with lower viral setpoints [34] . It appeared that the higher setpoint induced a greater level of immune activation, which resulted in high T-cell turnover being directly proportional to the level of viremia [13, 35] . This study confirms the direct association of high VL with rapid CD4 + cell loss, which, in turn, is related to levels of T-cell activation [36] . Collectively, these data suggest that recognition of class I HLA-restricted variant epitopes and the late stage of CD8 + memory differentiation are concentrated in women with rapid disease progression. We have previously shown that the frequency of conserved HLA-B restricted epitopes is more abundant in non-rapid progressors [37] . The long-term follow-up of this cohort enabled us to describe the trajectory of clinical signs and symptoms occurring in these women. STIs (genital ulcers and discharge) were common during early infection, whereas other infections such as varicella and tuberculosis occurred later. This is likely because the former are co-transmitted, or are the result of reduced mucosal barrier function as a result of CD4 loss, whereas the latter require more advanced immunodeficiency. Although this cohort showed rapid immunologic progression, there was little evidence of severe clinical disease or early AIDS-defining illnesses within the first 3 years of infection [32] , compared with what has been observed in other cohorts. The most likely reason for this was the close follow-up of participants and prompt ART initiation prior to onset of AIDS.
A limitation of this acute HIV-infected cohort is the relatively small sample size, albeit comparable to similar cohorts, and our findings may therefore not be generalizable outside our setting. Because this was a female cohort, caution would need to be exercised when extrapolating these results on disease progression to the male population.
The rapid progression observed in this cohort provides additional motivation to implement earlier ART initiation. 
